Header Logo

Connection

MARY ESTES to Viral Vaccines

Back to Details
This is a "connection" page, showing publications MARY ESTES has written about Viral Vaccines.
MARY ESTES
Connection Strength
4.649
Viral Vaccines
  1. Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
    View in: PubMed
    Score: 0.731
  2. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.698
  3. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.520
  4. Norovirus vaccine development: next steps. Expert Rev Vaccines. 2012 Sep; 11(9):1023-5.
    View in: PubMed
    Score: 0.310
  5. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.182
  6. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003 Sep; 108(3):241-7.
    View in: PubMed
    Score: 0.166
  7. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 2001 Oct; 75(20):9713-22.
    View in: PubMed
    Score: 0.145
  8. Norwalk virus vaccines: challenges and progress. J Infect Dis. 2000 May; 181 Suppl 2:S367-73.
    View in: PubMed
    Score: 0.132
  9. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
    View in: PubMed
    Score: 0.118
  10. Viral gastroenteritis. Lancet. 2018 07 14; 392(10142):175-186.
    View in: PubMed
    Score: 0.116
  11. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol. 1998 Feb; 72(2):1345-53.
    View in: PubMed
    Score: 0.113
  12. Prospects and Challenges in the Development of a Norovirus Vaccine. Clin Ther. 2017 Aug; 39(8):1537-1549.
    View in: PubMed
    Score: 0.109
  13. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017 May; 24(5).
    View in: PubMed
    Score: 0.107
  14. Advances in molecular biology: impact on rotavirus vaccine development. J Infect Dis. 1996 Sep; 174 Suppl 1:S37-46.
    View in: PubMed
    Score: 0.102
  15. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996 Sep; 174 Suppl 1:S88-92.
    View in: PubMed
    Score: 0.102
  16. Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog. 2016 04; 12(4):e1005334.
    View in: PubMed
    Score: 0.100
  17. Rotavirus subunit vaccines. Arch Virol Suppl. 1996; 12:199-206.
    View in: PubMed
    Score: 0.098
  18. Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
    View in: PubMed
    Score: 0.097
  19. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.094
  20. Rotavirus vaccines and vaccination potential. Curr Top Microbiol Immunol. 1994; 185:285-337.
    View in: PubMed
    Score: 0.085
  21. Rotavirus vaccine administered parenterally induces protective immunity. J Virol. 1993 Nov; 67(11):6633-41.
    View in: PubMed
    Score: 0.084
  22. Rotaviruses: cause of vaccine-preventable disease yet many fundamental questions remain to be explored. Curr Opin Virol. 2012 Aug; 2(4):369-72.
    View in: PubMed
    Score: 0.077
  23. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.074
  24. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J. 2006 Jul; 4(4):419-32.
    View in: PubMed
    Score: 0.051
  25. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol. 1999 Jun; 73(6):4813-22.
    View in: PubMed
    Score: 0.031
  26. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol. 1998 Nov; 72(11):9233-46.
    View in: PubMed
    Score: 0.030
  27. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol. 1998 Apr; 72(4):3390-3.
    View in: PubMed
    Score: 0.029
  28. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol. 1997 Nov; 71(11):8707-17.
    View in: PubMed
    Score: 0.028
  29. Virus-like particle vaccines for mucosal immunization. Adv Exp Med Biol. 1997; 412:387-95.
    View in: PubMed
    Score: 0.026
  30. Antiviral targets of human noroviruses. Curr Opin Virol. 2016 06; 18:117-25.
    View in: PubMed
    Score: 0.025
  31. Recombinant Norwalk virus-like particles as an oral vaccine. Arch Virol Suppl. 1996; 12:243-9.
    View in: PubMed
    Score: 0.024
  32. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
    View in: PubMed
    Score: 0.022
  33. Molecular biology and immunology of rotavirus infections. Immunol Invest. 1989 Jan-May; 18(1-4):571-81.
    View in: PubMed
    Score: 0.015
  34. Analysis of host range restriction determinants in the rabbit model: comparison of homologous and heterologous rotavirus infections. J Virol. 1998 Mar; 72(3):2341-51.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.